In-Depth Analysis of Post-recurrence Survival in Resected Pancreatic Ductal Adenocarcinoma: A Cohort Study

Clicks: 1
ID: 315784
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #353 of 432 articles by views in the british journal of surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Recurrence after curative-intent resection of pancreatic ductal adenocarcinoma (PDAC) is frequent, however post-recurrence survival (PRS) may vary widely. Aims To analyze in depth PRS and identify the prognostic factors associated with it. Methods Retrospective cohort study including patients with PDAC recurrence after pancreatectomy. PRS was estimated with the Kaplan Meier method in the whole cohort and in subgroups based on performance status (ECOG-PS) at recurrence, timing, pattern, treatment of recurrence. Prognostic factors of PRS were evaluated through a Cox regression model. Results Seventy patients who underwent pancreatic resection (pancreatoduodenectomy, n=49; distal pancreatectomy, n=19; total pancreatectomy, n=2), and experienced PDAC recurrence, were included. R0, pN+ and perineural invasion rates were 72.9%, 67.1% and 94.3% respectively. Neoadjuvant and adjuvant chemotherapy were administered in 34.3% and 70% respectively. Recurrences were in multiple sites (51.4%), peritoneal-only (18.6%), hepatic-only (7.1%), isolated local (11.4%), pulmonary-only (1.4%). Early recurrence (<1 year after pancreatectomy) occurred in 41 cases (58.6%). Mean recurrence-free survival was 14.0 months; mean PRS was 13.0 months in the whole cohort. In subgroup analyses, patients with low ECOG-PS (0-1) had longer PRS than those with high ECOG-PS (>1) (log-rank=42.1; p>0.001). Conversely, PRS was similar in patients in early vs. late recurrences (log-rank=1.110; p=0.292) and by site of recurrence (log-rank=2.39; p=0.664). Recurrence treatment with chemotherapy, radical surgery or both was associated with longer PRS compared to radiotherapy, palliative surgery or best supportive care (log-rank=35.7; p<0.001). Cox regression analysis found R0 resection after index pancreatectomy (HR=0.44), low ECOG-PS at recurrence (HR=0.18) and treatment of recurrence by chemotherapy, surgery or both (HR=0.34), to be independently associated with a lower cumulative risk of death after recurrence. Borderline/locally-advanced PDAC and multisite recurrences tended toward worse PRS. Conclusion PRS seems influenced by patients' conditions at recurrence and the feasibility of effective treatments (including surgery), rather than only by surrogates of biology of the disease (initial resectability status, timing/pattern of recurrence).
Reference Key
openalex_W7163416087 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors L Bernardi, E Garosi, R Roesel, G Salina, L Deantonio, M Cefalì, G Pesola, P Majno-Hurst, S de Dosso, A Cristaudi
Journal the british journal of surgery
Year 2026
DOI
10.1093/bjs/znag055.032
URL
https://doi.org/10.1093/bjs/znag055.032
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.